Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 at a 5.3% CAGR - ResearchAndMarkets.com

The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, November 24, 2022
Information
Tags: 
Health, Pharmaceutical, COVID-19, Pet
Geotags: 
JAPAN, EUROPE, CHINA, CANADA, US, GERMANY
Organisation: 
RESEARCH AND MARKETS
Summary
Key Points: 
  • The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR
    The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027.


The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.

The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured) -

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Companies Mentioned

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv

Copyright: 
Copyright Business Wire 2022